| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NN.3435 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nn.3435 |
| P932 | PMC publication ID | 3703870 |
| P698 | PubMed publication ID | 23708142 |
| P5875 | ResearchGate publication ID | 262043301 |
| P50 | author | Alzheimer's Disease Neuroimaging Initiative | Q4738819 |
| Linda Ottoboni | Q42772797 | ||
| Denis Evans | Q64706335 | ||
| David A Bennett | Q66739430 | ||
| Julie A. Schneider | Q67212579 | ||
| Martha Clare Morris | Q86729995 | ||
| Philip L. De Jager | Q87721560 | ||
| Elizabeth M Bradshaw | Q89698760 | ||
| Lori B Chibnik | Q91244792 | ||
| P2093 | author name string | Brendan T Keenan | |
| Towfique Raj | |||
| Reisa A Sperling | |||
| Keith Johnson | |||
| Michelle Lee | |||
| Anna Tang | |||
| Alina Von Korff | |||
| Selina Imboywa | |||
| Laura L Rosenkrantz | |||
| P2860 | cites work | Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents | Q44474556 |
| Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling | Q45186177 | ||
| Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis | Q46837688 | ||
| Increased pro-inflammatory response by dendritic cells from patients with Alzheimer's disease | Q48328855 | ||
| Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. | Q50742360 | ||
| Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. | Q50758048 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| Activated microglia in dementia with Lewy bodies. | Q53236387 | ||
| Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. | Q53388052 | ||
| Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease | Q57306418 | ||
| Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease | Q73789480 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| “Mini-mental state” | Q25938989 | ||
| Testing the right target and right drug at the right stage | Q26864854 | ||
| Principal components analysis corrects for stratification in genome-wide association studies | Q27860975 | ||
| Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease | Q28943325 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| GenePattern 2.0 | Q29614171 | ||
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | Q29614879 | ||
| Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 | ||
| Adjusting batch effects in microarray expression data using empirical Bayes methods | Q29614937 | ||
| Development and validation of a geriatric depression screening scale: a preliminary report | Q29615638 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| Disruption of functional connectivity in clinically normal older adults harboring amyloid burden | Q30492809 | ||
| Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. | Q33697980 | ||
| Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study | Q34279689 | ||
| Genome-wide analysis of genetic loci associated with Alzheimer disease | Q34339530 | ||
| Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects | Q34356874 | ||
| Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains | Q34506196 | ||
| Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study | Q35168704 | ||
| Overview and findings from the religious orders study | Q36130996 | ||
| Overview and findings from the rush Memory and Aging Project | Q36226167 | ||
| Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease | Q36893432 | ||
| Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta | Q36996975 | ||
| Imaging amyloid deposition in Lewy body diseases | Q37087766 | ||
| A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease | Q37465017 | ||
| Alzheimer's disease genetics: current knowledge and future challenges | Q37801363 | ||
| Neuropathology of older persons without cognitive impairment from two community-based studies | Q38405842 | ||
| Design of the Chicago Health and Aging Project (CHAP). | Q39670365 | ||
| Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. | Q40415499 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 848-850 | |
| P577 | publication date | 2013-05-23 | |
| P1433 | published in | Nature Neuroscience | Q1535359 |
| P1476 | title | CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology | |
| P478 | volume | 16 |
| Q91973479 | A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease |
| Q35702861 | A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology |
| Q40154608 | A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. |
| Q47269263 | A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. |
| Q48092039 | A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain |
| Q37394169 | ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status |
| Q35543248 | APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages |
| Q28085213 | APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective |
| Q91487388 | Activated microglia desialylate their surface, stimulating complement receptor 3-mediated phagocytosis of neurons |
| Q33727947 | Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. |
| Q90351471 | Alzheimer Disease: An Update on Pathobiology and Treatment Strategies |
| Q45395821 | Alzheimer disease: functional dissection of CD33 locus implicates innate immune response in Alzheimer disease pathology |
| Q47149654 | Alzheimer's Disease: From Genetic Variants to the Distinct Pathological Mechanisms |
| Q26778149 | Alzheimer's Disease: Mechanism and Approach to Cell Therapy |
| Q28085139 | Alzheimer's disease: Unique markers for diagnosis & new treatment modalities |
| Q104134876 | Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer's disease |
| Q93014137 | Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses |
| Q28391826 | Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease |
| Q36999150 | Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease |
| Q48606515 | Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance. |
| Q35339698 | Association of Alzheimer's disease GWAS loci with MRI markers of brain aging |
| Q35044486 | Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex |
| Q91675228 | Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer's disease |
| Q48361868 | Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease. |
| Q41217789 | Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice. |
| Q99631048 | Brain tocopherol levels are associated with lower activated microglia density in elderly human cortex |
| Q33745617 | Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease |
| Q92830489 | CD22 blockade restores homeostatic microglial phagocytosis in ageing brains |
| Q64241083 | CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway |
| Q37093860 | CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. |
| Q46426075 | CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. |
| Q38132067 | CD33 in Alzheimer's disease |
| Q36381165 | CD33 modulates TREM2: convergence of Alzheimer loci. |
| Q39135360 | CD33 rs3865444 Polymorphism Contributes to Alzheimer's Disease Susceptibility in Chinese, European, and North American Populations |
| Q37708389 | CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility |
| Q37719159 | Can MRI T1 be used to detect early changes in 5xFAD Alzheimer's mouse brain? |
| Q38658658 | Central nervous system myeloid cells as drug targets: current status and translational challenges |
| Q36765873 | Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant. |
| Q38204711 | Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery |
| Q39135845 | Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. |
| Q90282526 | Comprehensive cell surface proteomics defines markers of classical, intermediate and non-classical monocytes |
| Q90376750 | Contributions of monocytes to nervous system disorders |
| Q24338376 | Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase |
| Q37713734 | Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample |
| Q91706665 | Deep Feature Selection and Causal Analysis of Alzheimer's Disease |
| Q42683481 | Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. |
| Q48141250 | Differential contribution of microglia and monocytes in neurodegenerative diseases. |
| Q40240888 | Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. |
| Q40415354 | Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas |
| Q59128213 | Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APP/PS1 Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease |
| Q64273242 | Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target? |
| Q28555197 | Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining |
| Q35671748 | Effect of APOE and CD33 on Cognitive Decline |
| Q30805627 | Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. |
| Q55379242 | Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. |
| Q34518584 | Epigenomics of Alzheimer's disease |
| Q92865495 | Evaluation of CD33 as a genetic risk factor for Alzheimer's disease |
| Q37282153 | Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease |
| Q92535560 | Friend, Foe or Both? Immune Activity in Alzheimer's Disease |
| Q50533255 | Frontotemporal dysregulation of the SNARE protein interactome is associated with faster cognitive decline in old age. |
| Q59136184 | Functional alterations of myeloid cells during the course of Alzheimer's disease |
| Q37508556 | Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms |
| Q31162702 | Future Directions in Imaging Neurodegeneration |
| Q36351585 | GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. |
| Q38728718 | Gemtuzumab ozogamicin in acute myeloid leukemia |
| Q37219530 | Gene-based aggregate SNP associations between candidate AD genes and cognitive decline |
| Q26747803 | Genes associated with Alzheimer's disease: an overview and current status |
| Q26801647 | Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans |
| Q91796279 | Genetic variability in response to amyloid beta deposition influences Alzheimer's disease risk |
| Q26781865 | Genetics ignite focus on microglial inflammation in Alzheimer's disease |
| Q35837399 | Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. |
| Q54995495 | Genome-wide significant risk factors on chromosome 19 and the APOE locus. |
| Q40096936 | Genome-wide significant, replicated and functional risk variants for Alzheimer's disease. |
| Q38822996 | Genomics of Alzheimer Disease: A Review. |
| Q38370663 | Glia: guardians, gluttons, or guides for the maintenance of neuronal connectivity? |
| Q47434009 | Glial Draper Rescues Aβ Toxicity in a Drosophila Model of Alzheimer's Disease |
| Q92528170 | Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders |
| Q36262517 | High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect to Aging and Genetic Factors. |
| Q38379615 | Hippocampal formation alterations differently contribute to autobiographic memory deficits in mild cognitive impairment and Alzheimer's disease |
| Q58761831 | Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology |
| Q90206556 | Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases |
| Q28602637 | Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline |
| Q46033933 | Human-specific evolutionary changes in the biology of siglecs. |
| Q38492631 | Immune attack: the role of inflammation in Alzheimer disease. |
| Q91451790 | Immunophenotypes associated with bipolar disorder and lithium treatment |
| Q44559358 | Impacts of CD33 Genetic Variations on the Atrophy Rates of Hippocampus and Parahippocampal Gyrus in Normal Aging and Mild Cognitive Impairment |
| Q91129691 | Implications of sleep disturbance and inflammation for Alzheimer's disease dementia |
| Q37031576 | Increased tauopathy drives microglia-mediated clearance of beta-amyloid. |
| Q38605546 | Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease |
| Q90333330 | Inferring the Molecular Mechanisms of Noncoding Alzheimer's Disease-Associated Genetic Variants |
| Q58700943 | Inflammation: the link between comorbidities, genetics, and Alzheimer's disease |
| Q55289589 | Innate immune activation in Alzheimer’s disease. |
| Q38223011 | Innate immune activation in neurodegenerative disease |
| Q38358574 | Innate immunity in Alzheimer's disease |
| Q27003132 | Integration of multiscale dendritic spine structure and function data into systems biology models |
| Q36553764 | Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk |
| Q28394967 | Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors |
| Q89461791 | Interleukin-12/23 deficiency differentially affects pathology in male and female Alzheimer's disease-like mice |
| Q91114669 | Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight |
| Q27014964 | Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways |
| Q46926746 | Let's make microglia great again in neurodegenerative disorders. |
| Q47920956 | Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review |
| Q27006789 | Mechanisms Underlying the Selection and Function of Macrophage-Specific Enhancers |
| Q38793938 | Microglia and brain macrophages: An update |
| Q30411278 | Microglia as a critical player in both developmental and late-life CNS pathologies |
| Q28074099 | Microglia communication: Parallels between aging and Alzheimer's disease |
| Q35030015 | Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques |
| Q59333255 | Microglia in Alzheimer's Disease: Risk Factors and Inflammation |
| Q56922819 | Microglia in Alzheimer's disease |
| Q52918308 | Microglia in Health and Disease. |
| Q57153215 | Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice |
| Q38195641 | Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis |
| Q38681675 | Microglia-blood vessel interactions: a double-edged sword in brain pathologies |
| Q38785333 | Microglia: Architects of the Developing Nervous System |
| Q90049859 | Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development |
| Q54988763 | Microglial Lectins in Health and Neurological Diseases. |
| Q36348184 | Microglial malfunction: the third rail in the development of Alzheimer's disease |
| Q38196699 | Microglial priming in neurodegenerative disease |
| Q91393803 | Microglial signatures and their role in health and disease |
| Q57183034 | Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells |
| Q38666481 | Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells |
| Q39249384 | Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids |
| Q38962283 | Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets |
| Q89965814 | Murine Gut Microbiome Association With APOE Alleles |
| Q26770676 | Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases |
| Q31142833 | Neuroinflammation - using big data to inform clinical practice |
| Q28259238 | Neuroinflammation in Alzheimer's disease |
| Q50106151 | Neuroinflammation: Microglia and T Cells Get Ready to Tango. |
| Q90077292 | Neurosteroids as regulators of neuroinflammation |
| Q99238404 | Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease |
| Q50072580 | Noncoding RNAs in Alzheimer's disease. |
| Q34147513 | Ontogeny and functions of central nervous system macrophages. |
| Q94545248 | Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives |
| Q36073671 | Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease |
| Q36509219 | Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease |
| Q35804607 | Platelet dysfunction in hypercholesterolemia mice, two Alzheimer's disease mouse models and in human patients with Alzheimer's disease |
| Q37012919 | Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes |
| Q64864693 | Polygenic analysis of inflammatory disease variants and effects on microglia in the aging brain |
| Q35470763 | Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease |
| Q64082784 | Prioritizing Parkinson's disease genes using population-scale transcriptomic data |
| Q34508284 | Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration |
| Q64099249 | Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease |
| Q30360331 | Regulation of microglial survival and proliferation in health and diseases. |
| Q88978899 | Religious Orders Study and Rush Memory and Aging Project |
| Q91794247 | Repression of phagocytosis by human CD33 is not conserved with mouse CD33 |
| Q92823426 | SRSF1 and PTBP1 Are trans-Acting Factors That Suppress the Formation of a CD33 Splicing Isoform Linked to Alzheimer's Disease Risk |
| Q34429207 | SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease |
| Q57143986 | Sexual dimorphism in predisposition to Alzheimer's disease |
| Q104503342 | Sialylation acts as a checkpoint for innate immune responses in the central nervous system |
| Q34314957 | Siglec-mediated regulation of immune cell function in disease. |
| Q90224834 | Siglecs in Brain Function and Neurological Disorders |
| Q39304295 | Single-Cell RNA Sequencing: Unraveling the Brain One Cell at a Time. |
| Q92028938 | Sleep fragmentation, microglial aging, and cognitive impairment in adults with and without Alzheimer's dementia |
| Q92342638 | Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis |
| Q28069506 | Stem Cell Therapy: A Prospective Treatment for Alzheimer's Disease |
| Q34463760 | Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration |
| Q92270621 | Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome |
| Q38239646 | Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy |
| Q37672845 | T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers |
| Q90320717 | TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia |
| Q51743108 | TNF alpha inhibitors in Alzheimer's disease: A systematic review. |
| Q59812403 | TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism |
| Q26785919 | TREM2 in CNS homeostasis and neurodegenerative disease |
| Q38748724 | TREM2 variants: new keys to decipher Alzheimer disease pathogenesis |
| Q61772841 | TREM2 — a key player in microglial biology and Alzheimer disease |
| Q53376999 | Targeting microglia for the treatment of Alzheimer's Disease. |
| Q89505497 | Tensor decomposition of stimulated monocyte and macrophage gene expression profiles identifies neurodegenerative disease-specific trans-eQTLs |
| Q53096518 | The 14th International Conference on Alzheimer's Drug Discovery, 9 - 10 September 2013, in Jersey City, New Jersey. |
| Q58616645 | The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study |
| Q37261981 | The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease |
| Q90275177 | The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques |
| Q55416173 | The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. |
| Q90454167 | The Role of Microglia in the Spread of Tau: Relevance for Tauopathies |
| Q36659056 | The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function |
| Q108768848 | The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans |
| Q38423147 | The dynamics of monocytes and microglia in Alzheimer's disease |
| Q35064995 | The evolving biology of microglia in Alzheimer's disease. |
| Q87676624 | The genetics of Alzheimer's disease |
| Q37341692 | The microglial sensome revealed by direct RNA sequencing |
| Q42656274 | The roles of inflammation and immune mechanisms in Alzheimer's disease |
| Q92350333 | Trained Innate Immunity Not Always Amicable |
| Q37129602 | Trans-pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci |
| Q41116769 | Unraveling the genes implicated in Alzheimer's disease |
| Q39407560 | Untangling Genetic Risk for Alzheimer's Disease |
| Q33784904 | YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies |
| Q38759253 | YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease |
| Q46001503 | iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. |
| Q35788393 | β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation |
| Q91581374 | γ-Secretase and its modulators: Twenty years and beyond |
Search more.